Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | PRKCA | P17252 | 4/20 | 0.69 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.69 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.69 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.69 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.65 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.65 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055170 | 1.00 | ALDH1A1 (0.81) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL9955111 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL896443 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL8908785 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL23612380 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL24334040 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL24333843 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL24334742 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL22973398 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL24333834 | 0.90 | ALDH1A1 (1.00) | ALDH1A1LMNAPRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20170326103-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2017-11-16 | — | — | US | disclosed |
| US-7629003-B2 | Esters of L-carnitine of alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-12-08 | — | — | US | disclosed |
| US-7629003-B2 | Esters of L-carnitine of alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-12-08 | — | — | US | disclosed |
| US-7585519-B2 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-09-08 | — | — | US | disclosed |
| US-7585519-B2 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-09-08 | — | — | US | disclosed |
| US-20070190128-A1 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-08-16 | — | — | US | disclosed |
| US-20070190128-A1 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-08-16 | — | — | US | disclosed |
| US-20050079209-A1 | Esters of L-carnitine of alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. | 2005-04-14 | — | — | US | disclosed |
| EP-1183228-B1 | ESTERS OF L-CARNITINE OR ALKANOYL L-CARNITINES USEFUL AS CATIONIC LIPIDS FOR THE INTRACELLULAR DELIVERY OF PHARMACOLOGICALLY ACTIVE COMPOUNDS. | SIGMA TAU IND FARMACEUTI (IT) | 2005-01-12 | — | — | EP | disclosed |
| US-6797281-B1 | Esters of I-carnitine or alkanoyl I-carnitines | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-09-28 | — | — | US | disclosed |
| US-20040186175-A1 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | ALDH1A1 1218/4885LMNA 2962/4885PRKCA 2982/4885 |
| US-20050079209-A1 | Esters of L-carnitine of alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SLC25A20, CRAT, CPT1B | ALDH1A1 628/4885LMNA 256/4885PRKCA 1547/4885 |
| US-20040186175-A1 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | CPT1B, SLC25A20, CRAT | ALDH1A1 461/4885LMNA 297/4885PRKCA 1645/4885 |
| US-20070190128-A1 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | CRAT, SLC25A20, CPT1B | ALDH1A1 637/4885LMNA 238/4885PRKCA 1495/4885 |
| US-20170326103-A1 | LYMPH DIRECTING PRODRUGS | LTA, ABCB11, LYN | ALDH1A1 1056/4885LMNA 3766/4885PRKCA 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.